"Behind the Buzz" Show: Dyadic International, Inc. (NASDAQ: DYAI) Managing Director Matthew S. Jones | Financial Buzz

“Behind the Buzz” Show: Dyadic International, Inc. (NASDAQ: DYAI) Managing Director Matthew S. Jones

Financialbuzz.com’s Latest Behind the Buzz Show: Exclusive Interview with MANAGING DIRECTOR, BUSINESS DEVELOPMENT & LICENSING Matthew S. Jones of Dyadic International, Inc. Live at the Bio CEO & Investor Conference

Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives.

MATTHEW S. JONES: MANAGING DIRECTOR, BUSINESS DEVELOPMENT & LICENSING

Mr. Jones has led and transformed commercial growth and M&A strategies for a diverse range of science businesses both in Europe and the US.  Prior to joining Dyadic he served as Chief Commercial Officer for Concept Life Sciences from its formation until 2016 –  prior to that, Mr. Jones was Vice President of Global Sales & Business Development at Lonza Biologics, where he implemented new income-generating streams alongside capturing enterprise and cross-divisional synergies in manufacturing, research and client/vendor relationships.  From 2009-2012 Mr. Jones served as Executive Vice President of Business Development & Marketing at Ricerca BioSciences LLC where key responsibilities included strategic deal making, royalty and asset license optimisation and marketing effectiveness. From 2003-2009 Mr. Jones was Senior Vice President of Business Development at MDS Pharma Services Inc. where he led the BioPharmaceutical commercial growth platforms. Mr. Jones has also held senior level biologic and clinical leadership roles within the biopharmaceutical industry with Alkermes, Inc. and from 1998 with GlaxoSmithKline PLC.

Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. Experience the best of biotech with two days of productive partnering meetings with institutional and early-stage investors, industry analysts, and senior biotechnology executives, in one location.

For more information, please visit: Dyadic International, Inc.

About Behind the Buzz: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.